Cencora, Inc. $COR Shares Sold by CreativeOne Wealth LLC

CreativeOne Wealth LLC reduced its stake in Cencora, Inc. (NYSE:COR) by 51.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,980 shares of the company’s stock after selling 3,119 shares during the quarter. CreativeOne Wealth LLC’s holdings in Cencora were worth $931,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of COR. Cornerstone Wealth Group LLC raised its holdings in shares of Cencora by 1.3% in the third quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock worth $745,000 after buying an additional 30 shares during the last quarter. Security Financial Services INC. lifted its stake in shares of Cencora by 2.6% during the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock worth $414,000 after buying an additional 33 shares during the period. Hemington Wealth Management grew its holdings in shares of Cencora by 12.0% during the third quarter. Hemington Wealth Management now owns 327 shares of the company’s stock valued at $102,000 after buying an additional 35 shares during the last quarter. Quadcap Wealth Management LLC grew its holdings in shares of Cencora by 1.5% during the second quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock valued at $722,000 after buying an additional 36 shares during the last quarter. Finally, Howard Capital Management Inc. increased its position in shares of Cencora by 2.5% in the 3rd quarter. Howard Capital Management Inc. now owns 1,499 shares of the company’s stock valued at $468,000 after acquiring an additional 37 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the sale, the chief executive officer directly owned 66,726 shares in the company, valued at $23,669,713.98. This trade represents a 7.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at $8,173,111.10. The trade was a 12.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 15,220 shares of company stock worth $5,282,867 in the last ninety days. Company insiders own 0.38% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Bank of America reduced their target price on Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research note on Monday, January 5th. Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Jefferies Financial Group raised Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Wells Fargo & Company lifted their target price on Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Finally, JPMorgan Chase & Co. upped their target price on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $399.00.

Cencora Trading Down 0.6%

Shares of NYSE:COR opened at $350.15 on Thursday. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. Cencora, Inc. has a 12-month low of $251.94 and a 12-month high of $377.54. The business has a 50 day moving average of $355.08 and a two-hundred day moving average of $337.60. The company has a market capitalization of $68.12 billion, a PE ratio of 42.09, a PEG ratio of 1.64 and a beta of 0.68.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. During the same quarter last year, the company earned $3.73 EPS. The business’s revenue was up 5.5% on a year-over-year basis. As a group, analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s dividend payout ratio is presently 28.85%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.